TWINGEN - protocol for an observational clinical biobank recall and biomarker study to identify individuals with high risk of Alzheimer's disease.
Eero VuoksimaaToni T SaariAino AaltonenSari AaltonenSanna-Kaisa HerukkaPaula Iso-MarkkuTarja KokkolaAija KyttäläSari KärkkäinenHilkka LiedesMiina OllikainenTeemu PalviainenIlona RuotsalainenAuli ToivolaMia UrjanssonTommi VasankariHenri Vähä-YpyäMarkus M ForsbergMikko HiltunenAnu JalankoReetta KälviäinenTeijo KuopioJaakko LähteenmäkiPia NybergMinna MännikköRaisa SerpiSanna Siltanennull nullAarno PalotieJaakko A KaprioHeiko RunzValtteri JulkunenPublished in: medRxiv : the preprint server for health sciences (2023)
A large sample of individuals is recruited from a representative biobank databaseUsing health registry information, we exclude those with documented AD or other neurological or psychiatric diseases that can affect cognition. Pre-screening limits the sending of unnecessary invitations and saves costsParticipants have up to 48 years of follow-up questionnaire and clinical data from the Finnish Twin Cohort study and these data can be combined with multifaceted Finnish health registry information. Previous genotype data is available in the biobank from all TWINGEN study participants.We assess the feasibility of remote cognitive testing and blood samples in large-scale screening of AD risk, translating to the requirements of intervention trials and clinical practiceLimitations of the study are a lack of gold standard biomarkers (cerebrospinal fluid, positron emission tomography imaging) and neurological examinations.
Keyphrases
- positron emission tomography
- randomized controlled trial
- mental health
- computed tomography
- healthcare
- public health
- electronic health record
- health information
- cerebrospinal fluid
- big data
- cross sectional
- risk assessment
- climate change
- brain injury
- social media
- deep learning
- cerebral ischemia
- pet ct
- health promotion
- patient reported